Primarily investigated for its potential in treating psychiatric disorders, particularly schizophrenia. It functions as a metabotropic glutamate receptor agonist, targeting glutamate pathways in the brain, which are often dysregulated in such conditions. Clinical trials have explored its efficacy in alleviating symptoms like hallucinations and cognitive impairments, offering a novel approach compared to traditional antipsychotics. Additionally, it has been studied for its role in reducing negative symptoms and improving overall patient outcomes, though further research is needed to fully establish its therapeutic benefits and safety profile.